1 July 2026

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held yesterday afternoon, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	**Votes for**	**% of votes cast for**	**Votes Against**	**% of votes cast against**	**Total votes cast**	**Total votes cast as % of ISC *(1)***	**Votes with-held *(2)***
1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2025 together with the directors' reports and auditor's report on those accounts	1,457,300	96.22	5,966	0.39	1,514,592	22.27	16,829
2. To approve the Directors' Remuneration Report	1,307,710	93.00	47,125	3.35	1,406,161	20.68	125,260

3. To re-appoint PKF Littlejohn LLP as auditors	1,441,698	95.73	13,011	0.86	1,506,035	22.15	25,386
4. To authorise the Audit Committee to determine the level of the auditor's remuneration	1,349,329	95.78	8,150	0.58	1,408,805	20.72	122,616
5. To authorise the re-appointment of Vladislav Sandler	1,454,810	95.68	14,398	0.95	1,520,534	22.36	10,887
6. To authorise the re-appointment of Alexis Sandler	1,371,163	91.14	81,931	5.45	1,504,420	22.12	27,001
7. To authorise the re-appointment of Sir Marc Feldmann	1,454,149	95.66	14,591	0.96	1,520,066	22.35	11,355
8. To authorise the re-appointment of Peter Redmond	1,224,477	81.31	230,108	15.28	1,505,911	22.15	25,510
9. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act.	1,242,853	87.03	133,834	9.37	1,428,013	21.00	103,378
Special Resolutions	**Votes for**	**% of votes cast for**	**Votes against**	**% of votes cast against**	**Total votes cast**	**Total votes cast as % of ISC (1)**	**Votes with-held (2)**
10. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act.	1,195,851	83.61	183,068	12.80	1,430,245	21.03	101,176

11. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting,	1,409,241	92.61	61,106	4.02	1,521,673	22.38	9,748

(1) The Company's issued share capital ("ISC") on 26 June 2026, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 6,799,961 ordinary shares.

(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Hemogenyx Pharmaceuticals plc — https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder — headquarters@hemogenyx.com

Peter Redmond, Director — peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP — Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

AlbR Capital Limited — Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.